TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Rutgers plans Camden campus nursing school Rutgers University Wednesday announced plans for a School of Nursing at its Camden Campus. feeds.bizjournals.com |
Sell Genzyme Near Term Due to Continued Manufacturing Challenges Yesterday, Genzyme (GENZ) provided a manufacturing update with regard to the production of its blockbuster drug Cerezyme, and Fabrazyme - treatments for Gaucher disease and Fabry disease, respectively. The company reiterated that the it has sanitized and restarted the bioreactors that produce both drugs. Importantly, Cerezyme remains on track for shipment in Q4/09. However, Fabrazyme shipments are expected to be delayed until mid-December. The reasons for this latest setback are two-fold. The Fabrazyme bioreactors were the last to be sanitized and ultimately restarted for production; and The Fabrazyme bioreactors are not producing as much product as they were before the Allston plant was shut-down for cleansing. Based on these challenges, the company has revised its FY2009 revenue guidance for Fabrazyme to $450 million from a previous range of $510 to $520 million. Cerezyme revenues were guided to come in at approximately $800 million for FY2009, which compares to the company's previous guidance for the lower end of between $750 million to $1 billion.Complete Story » seekingalpha.com |
ERT Reports Third Quarter 2009 Results (PR Newswire) eResearchTechnology, Inc. , , a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries, announced today results for the third quarter and nine-month period ended September 30, 2009. us.rd.yahoo.com |
Medicare's Rules Pinching Patients New Medicare payment rules that limit reimbursements for home-oxygen therapy have created hardships for some patients and medical suppliers. online.wsj.com |
NeoStem: BioInsurance for the Future M.E. Garza submits: When Robin L. Smith M.D., Chairman of the Board and Chief Executive Officer of NeoStem Inc. (AMEX:NBS) first got involved with the company three years ago, it was a four cent stock called “Phase III Medical.” The company was making investments in companies for pieces of royalties and revenues. To its credit, one of the companies Phase III was very interested in helping finance was a tiny company called NeoStem. Now, as the science of stem cells continues to advance, doctors have come to realize that in each of us, stem cells become less and less in quantity and quality. This is cue not only to aging, but also to our environment, the food we eat and various other health factors.Complete Story » seekingalpha.com |